Table 1. Characteristics of Patients by Factor Level and Treatment Group.
| Characteristic | By factor level, No. (%) of patients | P valuea | By treatment group and factor level, No. (%) of patients | P valuea,b | ||||
|---|---|---|---|---|---|---|---|---|
| Standard group | Experimental group | |||||||
| Age analysis (n = 10 804) | <65 y | ≥65 y | <65 y | ≥65 y | <65 y | ≥65 y | ||
| Patients, No. (%) | 7268 (67.3) | 3536 (32.7) | 3334 (67.5) | 1607 (32.5) | 3934 (67.1) | 1929 (32.9) | ||
| Sex | ||||||||
| Female | 5318 (73.2) | 1825 (51.6) | .20 | 2402 (72.0) | 768 (47.8) | 2916 (74.1) | 1057 (54.8) | .34 |
| Male | 1950 (26.8) | 1711 (48.4) | 932 (28.0) | 839 (52.2) | 1018 (25.9) | 872 (45.2) | ||
| Race/ethnicity | ||||||||
| Minority | 1434 (19.7) | 518 (14.6) | <.001 | 630 (18.9) | 234 (14.6) | 804 (20.4) | 284 (14.7) | .89 |
| Not minority | 5834 (80.3) | 3018 (85.4) | 2704 (81.1) | 1373 (85.4) | 3130 (79.6) | 1645 (85.3) | ||
| PS | ||||||||
| Fully active | 5090 (70.0) | 1852 (52.4) | .002 | 2317 (69.5) | 792 (49.3) | 2773 (70.5) | 1060 (55.0) | .23 |
| <Fully active | 2178 (30.0) | 1684 (47.6) | 1017 (30.5) | 815 (50.7) | 1161 (29.5) | 869 (45.0) | ||
| Stage group | ||||||||
| Advanced | 2716 (37.4) | 2226 (63.0) | .06 | 1320 (39.6) | 1064 (66.2) | 1396 (35.5) | 1162 (60.2) | .20 |
| Not advanced | 4552 (62.6) | 1310 (37.0) | 2014 (60.4) | 543 (33.8) | 2538 (64.5) | 767 (39.8) | ||
| Sex analysis (n = 3946)c | Female | Male | Female | Male | Female | Male | ||
| Patients, No. (%) | 1483 (37.6) | 2463 (62.4) | 706 (37.6) | 1171 (62.4) | 777 (37.6) | 1292 (62.4) | ||
| Age, y | ||||||||
| <65 | 926 (62.4) | 1579 (64.1) | .15 | 448 (63.5) | 741 (63.3) | 478 (61.5) | 838 (64.9) | .36 |
| ≥65 | 557 (37.6) | 884 (35.9) | 258 (36.5) | 430 (36.7) | 299 (38.5) | 454 (35.1) | ||
| Race/ethnicity | ||||||||
| Minority | 302 (20.4) | 494 (20.1) | .20 | 137 (19.4) | 229 (19.6) | 165 (21.2) | 265 (20.5) | .69 |
| Not minority | 1181 (79.6) | 1969 (79.9) | 569 (80.6) | 942 (80.4) | 612 (78.8) | 1027 (79.5) | ||
| PS | ||||||||
| Fully active | 752 (50.7) | 1238 (50.3) | .78 | 360 (51.0) | 597 (51.0) | 392 (50.5) | 641 (49.6) | .46 |
| <Fully active | 731 (49.3) | 1225 (49.7) | 346 (49.0) | 574 (49.0) | 385 (49.5) | 651 (50.4) | ||
| Stage group | ||||||||
| Advanced | 826 (55.7) | 1638 (66.5) | .02 | 378 (53.5) | 759 (64.8) | 448 (57.7) | 879 (68.0) | .82 |
| Not advanced | 657 (44.3) | 825 (33.5) | 328 (46.5) | 412 (35.2) | 329 (42.3) | 413 (32.0) | ||
| Race/ethnicity analysis (n = 6990)d | Minority | Not Minority | Minority | Not Minority | Minority | Not Minority | ||
| Patients, No. (%) | 1431 (20.5) | 5559 (79.5) | 637 (20.0) | 2541 (80.0) | 794 (20.8) | 3018 (79.2) | ||
| Age, y | ||||||||
| <65 | 1084 (75.8) | 3626 (65.2) | <.001 | 483 (75.8) | 1651 (65.0) | 601 (75.7) | 1975 (65.4) | .66 |
| ≥65 | 347 (24.2) | 1933 (34.8) | 154 (24.2) | 890 (35.0) | 193 (24.3) | 1043 (34.6) | ||
| Sex | ||||||||
| Female | 882 (61.6) | 3821 (68.7) | .51 | 369 (57.9) | 1688 (66.4) | 513 (64.6) | 2133 (70.7) | .09 |
| Male | 549 (38.4) | 1738 (31.3) | 268 (42.1) | 853 (33.6) | 281 (35.4) | 885 (29.3) | ||
| PS | ||||||||
| Fully active | 835 (58.4) | 3646 (65.6) | .007 | 351 (55.1) | 1595 (62.8) | 484 (61.0) | 2051 (68.0) | .72 |
| <Fully active | 596 (41.6) | 1913 (34.4) | 286 (44.9) | 946 (37.2) | 310 (39.0) | 967 (32.0) | ||
| Stage group | ||||||||
| Advanced | 714 (49.9) | 2579 (46.4) | .82 | 347 (54.5) | 1283 (50.5) | 367 (46.2) | 1296 (42.9) | .31 |
| Not advanced | 717 (50.1) | 2980 (53.6) | 290 (45.5) | 1258 (49.5) | 427 (53.8) | 1722 (57.1) | ||
| Insurance analysis (n = 2255)e | M/NI | Private | M/NI | Private | M/NI | Private | ||
| Patients, No. (%) | 558 (24.7) | 1697 (75.3) | 240 (23.1) | 798 (76.9) | 318 (26.1) | 899 (73.9) | ||
| Sex | ||||||||
| Female | 347 (62.2) | 1025 (60.4) | .70 | 152 (63.3) | 459 (57.5) | 195 (61.3) | 566 (63.0) | .23 |
| Male | 211 (37.8) | 672 (39.6) | 88 (36.7) | 339 (42.5) | 123 (38.7) | 333 (37.0) | ||
| Race/ethnicity | ||||||||
| Minority | 297 (53.2) | 305 (18.0) | <.001 | 134 (55.8) | 140 (17.5) | 163 (51.3) | 165 (18.4) | .17 |
| Not minority | 261 (46.8) | 1392 (82.0) | 106 (44.2) | 658 (82.5) | 155 (48.7) | 734 (81.6) | ||
| PS | ||||||||
| Fully active | 272 (48.7) | 1017 (59.9) | <.001 | 106 (44.2) | 452 (56.6) | 166 (52.2) | 565 (62.8) | .71 |
| <Fully active | 286 (51.3) | 680 (40.1) | 134 (55.8) | 346 (43.4) | 152 (47.8) | 334 (37.2) | ||
| Stage group | ||||||||
| Advanced | 335 (60.0) | 1000 (58.9) | .86 | 157 (65.4) | 503 (63.0) | 178 (56.0) | 497 (55.3) | .68 |
| Not advanced | 223 (40.0) | 697 (41.1) | 83 (34.6) | 295 (37.0) | 140 (44.0) | 402 (44.7) | ||
Abbreviations: M/NI, Medicaid or no insurance; PS, performance status.
a
Determined from logistic regression accounting for study-level heterogeneity by specifying study as a random effect.
b
Represents whether the association between the factor and the category of interest differs between those receiving standard or experimental therapy, using an interaction test.
c
Analysis limited to patients enrolled to trials in non–sex-specific cancers only.
d
Analysis limited to patients with complete data on race/ethnicity.
e
Analysis limited to patients younger than 65 with private insurance or M/NI.